Article
Immunology
Wen Li, Shu Teng, Shi-Yong Zhao, Zheng-Hong Qi
Summary: This article reports a case of SIADH secondary to varicella in a 9-year-old girl with remarkable hyponatremia. The patient's serum sodium returned to the normal level under appropriate treatment and no evidence of hyponatremia was found at a 3-month follow-up. The authors suggest that the existence of SIADH should be considered when treating patients with varicella who present with severe hyponatremia.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2022)
Article
Pediatrics
Ankit Kumar Meena, Pamali Mahasweta Nanda, Rajni Sharma, Biswaroop Chakrabarty, Sheffali Gulati
Summary: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of euvolemic hyponatremia in hospitalized children. It is characterized by increased serum ADH, leading to water retention through V2 receptors in the distal renal tubules. The conventional treatment for SIADH includes fluid restriction and salt supplementation, but pharmacological therapy may be required in some cases. Limited experience exists with the use of V2-receptor antagonists in the pediatric population. In this case report, a girl with corpus callosum agenesis and severe symptomatic hyponatremia due to SIADH was successfully managed with the V2-receptor antagonist tolvaptan.
INDIAN JOURNAL OF PEDIATRICS
(2023)
Editorial Material
Clinical Neurology
Manabu Takano, Tsuyoshi Okada, Toshiyuki Kobayashi, Shiro Suda
Summary: This case report highlights a 77-year-old man with type 2 diabetes who developed hyponatremia (SIADH) 12 days after starting suvorexant for major depression treatment. The hyponatremia improved within 6 days of discontinuing suvorexant, suggesting a possible association between suvorexant and SIADH. Clinicians should be aware of this potential adverse effect despite the drug generally being considered relatively safe.
JOURNAL OF CLINICAL SLEEP MEDICINE
(2021)
Article
Medicine, General & Internal
Mari Mori, Satoru Takeshita, Nami Nakamura, Yuki Mizuno, Akiko Tomita, Mineyoshi Aoyama, Hiroki Kakita, Yasumasa Yamada
Summary: This report demonstrates the safety and efficacy of tolvaptan in an infant with HPE-associated SIADH.
WORLD JOURNAL OF CLINICAL CASES
(2023)
Article
Oncology
Tomoaki Takao, Kentaro Tanaka, Yoshimasa Shiraishi, Keiichi Ota, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto
Summary: A case of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a patient treated with osimertinib was described. The patient's condition improved after discontinuation of osimertinib treatment, and she was able to continue treatment with gefitinib without developing hyponatremia.
CLINICAL LUNG CANCER
(2021)
Editorial Material
Health Care Sciences & Services
Russell A. Wilke
Summary: SIADH is a common cause of hyponatremia, especially in elderly patients, and severe hyponatremia can have serious consequences. Further research is needed to develop decision support tools for identifying high-risk patients based on pharmacogenetic testing.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Medicine, General & Internal
Toru Hamada, Katsuyuki Matsuki, Seiji Kondou, Shinya Furukawa, Morikazu Onji
Summary: Duloxetine can cause syndrome of inappropriate secretion of antidiuretic hormone (SIADH), leading to hyponatremia. Elderly patients are more susceptible, with lower doses and earlier onset. Duloxetine-induced SIADH should be considered in high-risk elderly patients when hyponatremia occurs.
Article
Medicine, General & Internal
Kelash Kumar, F. N. U. Poonam, Teesha Rani, F. N. U. Prinka, Cece E. Ibeson, Ifeanyi Nwosu, Vijay Shetty, Anthony N. Kalloo
Summary: This case report highlights a rare case of a young Asian female addicted to the anesthetic ketamine, who presented with urinary complaints. The patient was found to have hyponatremia and was diagnosed with syndrome of inappropriate antidiuretic hormone (SIADH) release in the absence of other causes.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Oncology
Marcus Skribek, Benedek Bozoky, Georgios Tsakonas
Summary: Asian patients with EGFR-mutated NSCLC have a higher prevalence and may develop SIADH with osimertinib treatment, which can be significantly improved after discontinuation. Further studies are needed to evaluate the potential mechanisms of osimertinib-induced SIADH.
Review
Medicine, General & Internal
Esteban Poch, Alicia Molina, Gaston Pineiro
Summary: Hyponatremia is a common electrolyte disorder in hospitalized patients, with SIADH being a frequent cause that is mainly induced by factors such as cancer, pulmonary illnesses, central nervous system disorders, and various drugs. Diagnosis of SIADH by professionals often does not align with established criteria, potentially affecting therapeutic outcomes.
Review
Medicine, General & Internal
Lei Tian, Li-Ya He, Hong-Zhen Zhang
Summary: This case report describes a rare occurrence of SIADH induced by nedaplatin in a 54-year-old female with nasopharyngeal carcinoma. The side effects were effectively managed with fluid restriction and sodium supplementation, emphasizing the importance of cautiously treating life-threatening hyponatremia in patients receiving nedaplatin treatment.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Biochemistry & Molecular Biology
Yanhua Wang, Lauren M. LaRocque, Joseph A. Ruiz, Eva L. Rodriguez, Jeff M. Sands, Janet D. Klein
Summary: Hyponatremia is a water balance disorder due to abnormal renal diluting capacity. Vasopressin escape is a mechanism that limits the decrease in serum sodium concentration. Aldosterone and calcineurin play roles in regulating vasopressin escape through changes in UT-A1 and AQP2 proteins. Knockout mice lacking aldosterone synthase and rats treated with spironolactone or tacrolimus showed impaired vasopressin escape and altered protein abundances of UT-A1 and AQP2.
Article
Endocrinology & Metabolism
Hiroshi Arima, Koichi Goto, Tomohisa Motozawa, Makoto Mouri, Ryo Watanabe, Takahiro Hirano, San-e Ishikawa
Summary: The study demonstrated the efficacy and safety of tolvaptan in treating hyponatremia in Japanese patients with SIADH. Results showed that 81.3% of patients had normalized serum sodium concentration on the day after the final tolvaptan dose, with a mean change in serum sodium concentration of 11.0 ± 4.3 mEq/L. Adverse events related to tolvaptan were generally mild to moderate in severity.
Article
Pharmacology & Pharmacy
Koki Takeda, Chika Kobayashi, Taketo Nakai, Teruki Oishi, Akira Okada
Summary: The study analyzed the frequency and onset time of hyponatremia/SIADH induced by antidepressants and antipsychotics, finding that most drugs were associated with this risk and suggesting early attention to signs of hyponatremia/SIADH during drug administration. These findings could be useful in identifying and preventing early-stage AD- or AP-induced hyponatremia/SIADH and preventing it from progressing into a serious condition.
ANNALS OF PHARMACOTHERAPY
(2022)
Review
Medicine, General & Internal
Pajaree Krisanapan, Supawit Tangpanithandee, Charat Thongprayoon, Pattharawin Pattharanitima, Andrea Kleindienst, Jing Miao, Iasmina M. Craici, Michael A. Mao, Wisit Cheungpasitporn
Summary: This meta-analysis evaluates the safety and efficacy of vaptans in treating chronic hyponatremia in adult SIADH patients. The results indicate that vaptans effectively raise serum sodium concentration in the short-term, but caution is needed due to the risk of overcorrection.
JOURNAL OF CLINICAL MEDICINE
(2023)
